While Haemonetics Corp has underperformed by -0.37%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, HAE fell by -17.37%, with highs and lows ranging from $97.97 to $58.80, whereas the simple moving average fell by -24.50% in the last 200 days.
On February 07, 2025, BofA Securities Downgraded Haemonetics Corp (NYSE: HAE) to Underperform. A report published by JP Morgan on December 06, 2024, Initiated its previous ‘Overweight’ rating for HAE. Raymond James also Upgraded HAE shares as ‘Strong Buy’, setting a target price of $120 on the company’s shares in a report dated November 08, 2024. CL King Initiated an Buy rating on September 13, 2024, and assigned a price target of $116. BofA Securities initiated its ‘Neutral’ rating for HAE, as published in its report on September 11, 2024. BTIG Research’s report from September 10, 2024 suggests a price prediction of $112 for HAE shares, giving the stock a ‘Buy’ rating. Needham also rated the stock as ‘Buy’.
Analysis of Haemonetics Corp (HAE)
Further, the quarter-over-quarter increase in sales is 3.66%, showing a positive trend in the upcoming months.
Haemonetics Corp’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of 14.06% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.55, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and HAE has an average volume of 754.64K. On a monthly basis, the volatility of the stock is set at 4.77%, whereas on a weekly basis, it is put at 5.63%, with a loss of -13.94% over the past seven days. Furthermore, long-term investors anticipate a median target price of $96.80, showing growth from the present price of $61.31, which can serve as yet another indication of whether HAE is worth investing in or should be passed over.
How Do You Analyze Haemonetics Corp Shares?
Medical Instruments & Supplies giant Haemonetics Corp (HAE) is based in the USA and is one of the largest companies in the market. When comparing Haemonetics Corp shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 24.13, there is a growth in quarterly earnings of 21.92%.
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 1.59%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 113.11% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
HAE shares are owned by institutional investors to the tune of 113.11% at present.
